Glenmark launches Covid-19 drug FabiFlu, priced @ Rs 103 per tablet

Glenmark 409.35 Dated 19 Jun 2020

Upside-Target/Resistance : 475, 530 & 585
Downside-Support /Stoploss 400, 360 & 330

Drug firm Glenmark Pharmaceuticals has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate Covid-19 at a price of about Rs 103 per tablet.

The drug will be available as a 200 mg tablet at a maximum retail price (MRP)of Rs 3,500 for a strip of 34 tablets

FabiFlu is the first oral favipiravir-approved medication in India for the treatment of COVID-19

No Comments

Post A Comment